Home / Intelligence / White Papers / 2019 Trinity Drug Index
The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Navigating the Early Asset Evaluation Journey with Confidence
February 25, 2025 | 1:00 – 1:45 PM ET
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.
Sign Up Now
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More
Briefs
The “Molecular Optimizer” Archetype: A Strategy for First-Launch Companies to Streamline Their Path to Market
The “molecular optimizer” archetype is a strategy utilized by first-launch companies to optimize existing molecules when developing their first product. Companies using this approach tend to be small and emerging biotech firms that are seeking a foothold to enter the market. The primary benefit of this approach is that the method offers a higher probability […]
Read More